« Back to Record
Citation APA

Papagiannis, A., Majjaj, S., Duhoux, F. P., Agostinetto, E., Stanciu, M.-A., Vanhulst, T., Buisseret, L., Larsimont, D., Veys, I., Paesmans, M., Hammer, T. B., Awada, A., Ameye, L., Rothé, F., Madriles, F., Cash, T. T., Salgado, R., Willard-Gallo, K., Sotiriou, C., Vuylsteke, P., Neven, P., & Ignatiadis, M. (2025). Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study. Nature communications. doi:10.1038/s41467-025-66590-2


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/398093

Papagiannis, A., Majjaj, S., Duhoux, F. P., Agostinetto, E., Stanciu, M.-A., Vanhulst, T., Buisseret, L., Larsimont, D., Veys, I., Paesmans, M., Hammer, T. B., Awada, A., Ameye, L., Rothé, F., Madriles, F., Cash, T. T., Salgado, R., Willard-Gallo, K., Sotiriou, C., Vuylsteke, P., Neven, P., & Ignatiadis, M. (2025). Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study. Nature communications. doi:10.1038/s41467-025-66590-2